Dr. Sylvia Asa on Thyroid Cancer Genotyping
Dr. Sylvia Asa, MD, PhD, pathologist with the Toronto General Hospital/Research Institute (UHN) and a professor at the University of Toronto, discusses genotyping and the role it can play in diagnosing and selecting targeted treatments for thyroid cancer.
Dr. Sylvia Asa, MD, PhD, pathologist with the Toronto General Hospital/Research Institute (UHN) and a professor at the University of Toronto, discusses genotyping and the role it can play in diagnosing and selecting targeted treatments for thyroid cancer.
Targeted therapies based on genetic mutations are a more recent phenomenon in thyroid cancers, but pathologists have recognized phenotypes of thyroid cancer for more than 50 years that are based on genotypic findings but that don’t require the genotype to make a diagnosis, prognosis, or to determine predictive therapy, says Asa.
BRAF has emerged as the most common genetic mutation in thyroid cancer. However, unlike in most other BRAF-mutated cancers, BRAF-mutated thyroid cancers do not seem to respond well to targeted therapies. Understanding epigenetic changes may play an important role in better treating thyroid cancer, says Asa.
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
